Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Galapagos Unveils Third Drug Candidate For GSK
The latest pre-clinical candidate is a small molecule that meets all the chemical and biological criteria set by GSK for a potential new medicine. Galapagos developed the candidate
The latest pre-clinical candidate is a small molecule that meets all the chemical and biological criteria set by GSK for a potential new medicine. Galapagos developed the candidate
GSK also added that the report picked information from documents, which mischaracterized GlaxoSmithKline’s comprehensive efforts to research Avandia and communicated those findings to regulators, physicians and patients. GSK
Alliance Pharma has successfully raised £7.5m by way of a vendor share placing to part finance the initial cash element of the consideration for the acquisition. 28,846,154 new
Designed for both demanding research applications and routine laboratory analysis, the Lumina delivers 0.5nm spectral bandwidth, high sensitivity and fast scanning speed, providing performance for assay development, quantification
The controllers feature universal temperature sensor inputs to minimize stocking and design, a display that can exhibit change of status or alarm, having no need for an HMI,
This is the first of multiple trials that Merrimack and Sanofi-aventis expect to initiate in 2010 as part of a broad Phase 2 clinical development program for MM-121.
The Phase IIb trial is a multi-center, global, randomized, double-blind, placebo-controlled study in RSV-infected lung transplant patients with a primary endpoint of a reduction in incidence of new
Watson’s 174mg and 348mg strength bupropion hydrobromide tablet products are generic versions of Biovail’s Aplenzin ER, which is indicated for major depressive disorder. Reportedly, Biovail filed suit against
FDCA has made a plea to the state health ministry to allocate funds to include a software to the current system for the purpose. The agency is in
Based on this review, the DMC once again unanimously recommended continuation of the study as described in the FDA-agreed LibiGel safety study protocol, with no modifications. BioSante reported